DE60331584D1 - Modifizierte natriuretic verbindungen, konjugate und ihre verwendungen - Google Patents
Modifizierte natriuretic verbindungen, konjugate und ihre verwendungenInfo
- Publication number
- DE60331584D1 DE60331584D1 DE60331584T DE60331584T DE60331584D1 DE 60331584 D1 DE60331584 D1 DE 60331584D1 DE 60331584 T DE60331584 T DE 60331584T DE 60331584 T DE60331584 T DE 60331584T DE 60331584 D1 DE60331584 D1 DE 60331584D1
- Authority
- DE
- Germany
- Prior art keywords
- conjugates
- compounds
- disclosed
- natriuretic
- modified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L2203/00—Applications
- C08L2203/02—Applications for biomedical use
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42915102P | 2002-11-26 | 2002-11-26 | |
| PCT/US2003/037996 WO2004047871A2 (en) | 2002-11-26 | 2003-11-12 | Modified naturetic compounds, conjugates, and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE60331584D1 true DE60331584D1 (de) | 2010-04-15 |
Family
ID=32393512
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60331584T Expired - Lifetime DE60331584D1 (de) | 2002-11-26 | 2003-11-12 | Modifizierte natriuretic verbindungen, konjugate und ihre verwendungen |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7662773B2 (de) |
| EP (1) | EP1569683B1 (de) |
| JP (1) | JP2006515579A (de) |
| CN (1) | CN100558398C (de) |
| AT (1) | ATE459370T1 (de) |
| AU (2) | AU2003297583B2 (de) |
| BR (1) | BR0316560A (de) |
| CA (1) | CA2504287A1 (de) |
| DE (1) | DE60331584D1 (de) |
| HK (1) | HK1087327A1 (de) |
| PL (1) | PL377813A1 (de) |
| SG (1) | SG159387A1 (de) |
| WO (1) | WO2004047871A2 (de) |
Families Citing this family (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7524635B2 (en) * | 2003-04-17 | 2009-04-28 | Biosite Incorporated | Methods and compositions for measuring natriuretic peptides and uses thereof |
| AU2003268531A1 (en) | 2002-09-06 | 2004-03-29 | University Of South Florida | Materials and methods for treatment of allergic diseases |
| AU2003270427A1 (en) * | 2002-09-06 | 2004-03-29 | University Of South Florida | Cellular delivery of natriuretic peptides |
| US20080214437A1 (en) * | 2002-09-06 | 2008-09-04 | Mohapatra Shyam S | Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases |
| AU2003297583B2 (en) | 2002-11-26 | 2010-01-14 | Biocon, Ltd | Modified naturetic compounds, conjugates, and uses thereof |
| US7648962B2 (en) | 2002-11-26 | 2010-01-19 | Biocon Limited | Natriuretic compounds, conjugates, and uses thereof |
| AU2004264958B2 (en) | 2003-08-13 | 2010-04-15 | Biocon, Ltd | Micro-particle fatty acid salt solid dosage formulations for therapeutic agents |
| CA2559853A1 (en) * | 2004-02-17 | 2005-10-13 | University Of South Florida | Materials and methods for treatment of inflammatory and cell proliferation disorders |
| EP2348114B1 (de) | 2004-04-21 | 2018-07-25 | Alexion Pharmaceuticals, Inc. | Konjugate zur Zuführung an Knochen und Verfahren zu deren Verwendung beim Hinführen von Proteinen zum Knochen |
| WO2006005140A2 (en) | 2004-07-15 | 2006-01-19 | The University Of Queensland | Proteinaceous compounds and uses therefor |
| WO2006076471A2 (en) * | 2005-01-12 | 2006-07-20 | Nobex Corporation | Bnp conjugates and methods of use |
| US7300494B2 (en) * | 2005-02-24 | 2007-11-27 | Hamilton Sundstrand Corporation | On-board inert gas generation system with compressor surge protection |
| DK1865976T3 (da) | 2005-04-07 | 2012-07-23 | Cardiopep Pharma Gmbh | Anvendelse af natriuretiske peptider til behandling af hjertesvigt |
| KR101354244B1 (ko) | 2005-07-29 | 2014-02-18 | 넥타르 테라퓨틱스 | 폴리(에틸렌 글리콜) 의 카르보네이트 에스테르를 제조하는방법 |
| US7803901B2 (en) | 2005-09-16 | 2010-09-28 | Mayo Foundation For Medical Education And Research | Polypeptides with natriuresis activity |
| US8759290B2 (en) * | 2005-10-18 | 2014-06-24 | Biocon Limited | Oral glucagon-like peptide conjugates for metabolic diseases |
| CA2647143A1 (en) | 2006-03-30 | 2007-10-11 | Palatin Technologies, Inc. | Cyclic natriuretic peptide constructs |
| AU2007233123A1 (en) | 2006-03-30 | 2007-10-11 | Palatin Technologies, Inc. | Linear natriuretic peptide constructs |
| CA2656990A1 (en) * | 2006-04-28 | 2007-11-08 | University Of South Florida | Materials and methods for reducing inflammation by inhibition of the atrial natriuretic peptide receptor |
| JP5123936B2 (ja) | 2006-05-30 | 2013-01-23 | メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ | 認知症の検出および治療 |
| DK2037948T3 (en) | 2006-05-30 | 2016-08-01 | Mayo Foundation | Detection and treatment of dementia |
| US8486412B2 (en) | 2006-06-01 | 2013-07-16 | Mayo Foundation For Medical Education And Research | Immunity to folate receptors |
| US8008261B2 (en) | 2006-08-04 | 2011-08-30 | Mayo Foundation For Medical Education And Research | Methods of reducing trail-induced apoptosis by trail isoforms |
| US8283318B2 (en) * | 2006-09-08 | 2012-10-09 | Mayo Foundation For Medical Education And Research | Aquaretic and natriuretic polypeptides lacking vasodilatory activity |
| EP2146711A4 (de) | 2007-04-12 | 2011-10-26 | Univ Minnesota | Zusammensetzungen zum schutz vor ischämie/reperfusion und anwendungsverfahren |
| KR20080098216A (ko) * | 2007-05-04 | 2008-11-07 | 한미약품 주식회사 | 캐리어 물질을 이용한 나트륨 배설 펩타이드 약물 결합체 |
| JP2011504506A (ja) | 2007-11-21 | 2011-02-10 | バイオマリン ファーマシューティカル インコーポレイテッド | Ｃ型ナトリウム利尿ペプチドの変異体 |
| WO2009156481A1 (en) * | 2008-06-25 | 2009-12-30 | Ascendis Pharma As | Pegylated bnp |
| CA2737040C (en) | 2008-09-19 | 2017-05-02 | Nektar Therapeutics | Polymer conjugates of therapeutic peptides |
| US20110206633A1 (en) | 2008-09-19 | 2011-08-25 | Nektar Therapectics | Polymer conjugates of cd-np peptides |
| EP3175863B1 (de) | 2009-05-20 | 2021-12-01 | BioMarin Pharmaceutical Inc. | Varianten des natriuretischen peptids typ c |
| US20120108514A1 (en) | 2009-07-09 | 2012-05-03 | University Of Iowa Research Foundation | Long acting atrial natriuretic peptide (la-anp) and methods for use thereof |
| BR112012001491B1 (pt) | 2009-07-23 | 2022-03-15 | Igisu Co., Ltd | Preparação terapêutica para tratar dermatite e uso de uma preparação terapêutica |
| SG184860A1 (en) | 2010-04-27 | 2012-11-29 | Agency Science Tech & Res | Eif4e binding peptides |
| WO2012013597A1 (de) * | 2010-07-28 | 2012-02-02 | Justus-Liebig-Universität Giessen | Stoffe und deren verwendung zur beeinflussung natriuretischer peptidrezeptoren |
| CA2823066A1 (en) | 2010-12-27 | 2012-07-05 | Alexion Pharma International Sarl | Compositions comprising natriuretic peptides and methods of use thereof |
| EP2678002A2 (de) | 2011-02-25 | 2014-01-01 | Medtronic, Inc. | Therapie für nierenerkrankungen und/oder herzinsuffizienz |
| KR101969526B1 (ko) | 2011-02-28 | 2019-04-17 | 고쿠리츠켄큐카이하츠호진 고쿠리츠쥰칸키뵤 겐큐센터 | 악성 종양 전이 억제용 의약 |
| US10184942B2 (en) | 2011-03-17 | 2019-01-22 | University Of South Florida | Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer |
| CN103764165A (zh) | 2011-08-19 | 2014-04-30 | 独立行政法人国立循环器病研究中心 | 组合利尿钠肽受体gc-a激动剂以及gc-b激动剂而成的用于防止恶性肿瘤恶化的药品 |
| CN103906761B (zh) | 2011-08-30 | 2016-12-21 | 梅约医学教育与研究基金会 | 利钠多肽 |
| WO2013033675A1 (en) | 2011-09-02 | 2013-03-07 | Medtronic, Inc. | Chimeric natriuretic peptide compositions and methods of preparation |
| SG11201401605QA (en) | 2011-10-19 | 2014-09-26 | Alexion Pharma Holding | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
| US9611305B2 (en) | 2012-01-06 | 2017-04-04 | Mayo Foundation For Medical Education And Research | Treating cardiovascular or renal diseases |
| US20150315259A1 (en) * | 2012-03-19 | 2015-11-05 | Madeleine Phamaceuticals Pty Ltd | Method of producing a recombinant peptide |
| US10052366B2 (en) | 2012-05-21 | 2018-08-21 | Alexion Pharmaceuticsl, Inc. | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
| TW201442721A (zh) * | 2013-01-23 | 2014-11-16 | Daiichi Sankyo Co Ltd | 糖鏈修飾心房利尿鈉肽 |
| US10822596B2 (en) | 2014-07-11 | 2020-11-03 | Alexion Pharmaceuticals, Inc. | Compositions and methods for treating craniosynostosis |
| EP3226891A1 (de) | 2014-12-05 | 2017-10-11 | Alexion Pharmaceuticals, Inc. | Behandlung von krampfanfällen mit rekombinanter alkalischer phosphatase |
| US10603361B2 (en) | 2015-01-28 | 2020-03-31 | Alexion Pharmaceuticals, Inc. | Methods of treating a subject with an alkaline phosphatase deficiency |
| AU2016272282A1 (en) * | 2015-05-29 | 2018-01-25 | Igisu Co., Ltd. | Cyclic peptide, and medicine, external preparation and cosmetic each containing said cyclic peptide |
| US11352612B2 (en) | 2015-08-17 | 2022-06-07 | Alexion Pharmaceuticals, Inc. | Manufacturing of alkaline phosphatases |
| JP6868617B2 (ja) | 2015-09-28 | 2021-05-12 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 低ホスファターゼ血症の組織非特異的アルカリホスファターゼ（ｔｎｓａｌｐ）酵素補充療法に有効な投薬計画の特定 |
| JP2018533571A (ja) | 2015-10-30 | 2018-11-15 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 患者の頭蓋縫合早期癒合症を治療するための方法 |
| US11389510B2 (en) | 2016-01-08 | 2022-07-19 | Ascendis Pharma Growth Disorders A/S | Controlled-release CNP agonists with low initial NPR-B activity |
| IL259658B1 (en) | 2016-01-08 | 2024-02-01 | Ascendis Pharma Growth Disorders As | Controlled-release CNP agonists with reduced side effects |
| PL3400019T3 (pl) * | 2016-01-08 | 2023-01-23 | Ascendis Pharma Growth Disorders A/S | Proleki cnp z przyłączeniem nośnika w ugrupowaniu pierścieniowy |
| AU2017205690B2 (en) | 2016-01-08 | 2022-04-28 | Ascendis Pharma Growth Disorders A/S | Controlled-release CNP agonists with increased NEP stability |
| KR102518217B1 (ko) * | 2016-01-08 | 2023-04-04 | 아센디스 파마 그로우쓰 디스오더스 에이/에스 | 낮은 npr-c 결합을 갖는 제어 방출성 cnp 작용제 |
| WO2017118693A1 (en) * | 2016-01-08 | 2017-07-13 | Ascendis Pharma Growth Disorders A/S | Cnp prodrugs with large carrier moieties |
| EP3426286A4 (de) | 2016-03-08 | 2019-12-04 | Alexion Pharmaceuticals, Inc. | Verfahren zur behandlung von hypophosphatasie bei kindern |
| US11186832B2 (en) | 2016-04-01 | 2021-11-30 | Alexion Pharmaceuticals, Inc. | Treating muscle weakness with alkaline phosphatases |
| WO2017173395A1 (en) | 2016-04-01 | 2017-10-05 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in adolescents and adults |
| US10988744B2 (en) | 2016-06-06 | 2021-04-27 | Alexion Pharmaceuticals, Inc. | Method of producing alkaline phosphatase |
| US11116821B2 (en) | 2016-08-18 | 2021-09-14 | Alexion Pharmaceuticals, Inc. | Methods for treating tracheobronchomalacia |
| US10307398B2 (en) | 2016-09-20 | 2019-06-04 | Regents Of The University Of Minnesota | Resuscitation composition and methods of making and using |
| EP4223309A1 (de) * | 2016-09-29 | 2023-08-09 | Ascendis Pharma Growth Disorders A/S | Kombinationstherapie mit cnp-agonisten mit gesteuerter freisetzung |
| EP3538131A4 (de) | 2016-11-09 | 2020-07-01 | Mayo Foundation for Medical Education and Research | Manp-analoga |
| BR112019019720A2 (pt) * | 2017-03-22 | 2020-04-28 | Pharmain Corp | agonistas de npra, composições e usos dos mesmos |
| EP3600383A4 (de) | 2017-03-31 | 2020-10-28 | Alexion Pharmaceuticals, Inc. | Verfahren zur behandlung von hypophosphatasie (hpp) bei erwachsenen und jugendlichen |
| EP3678704A4 (de) | 2017-09-05 | 2021-09-01 | Torque Therapeutics, Inc. | Umkehrbare linker und verwendung davon |
| AU2018328209A1 (en) | 2017-09-05 | 2020-04-23 | Torque Therapeutics, Inc. | Therapeutic protein compositions and methods of making and using the same |
| EP3770143A4 (de) | 2018-03-20 | 2021-12-22 | NOF Corporation | Verzweigtes monodisperses polyethylenglykol, zwischenprodukt und verfahren zu seiner herstellung |
| WO2019190752A1 (en) | 2018-03-30 | 2019-10-03 | Alexion Pharmaceuticals, Inc. | Manufacturing of glycoproteins |
| KR102022118B1 (ko) * | 2019-01-07 | 2019-09-18 | 주식회사 아스트로젠 | 중추신경계 질환의 예방 또는 치료용 세린 유도체 화합물 |
| CN110278941B (zh) * | 2019-07-11 | 2021-05-28 | 西安国际医学中心有限公司 | 一种含有钠尿肽的离体心脏保护液 |
| CN111848776B (zh) * | 2020-08-31 | 2022-03-18 | 江苏璟泽生物医药有限公司 | 聚乙二醇修饰的rhBNP及其制备方法 |
| CN111978390B (zh) * | 2020-08-31 | 2022-10-14 | 上海景泽生物技术有限公司 | 聚乙二醇修饰的rhBNP及其用途 |
| WO2023039392A1 (en) * | 2021-09-07 | 2023-03-16 | Mayo Foundation For Medical Education And Research | Methods and materials for determining pgc target dosage |
| CN114316020A (zh) * | 2021-12-28 | 2022-04-12 | 南京岚煜生物科技有限公司 | 一种bnp重组蛋白及其制备方法和应用 |
Family Cites Families (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4044196A (en) * | 1972-03-30 | 1977-08-23 | Bayer Aktiengesellschaft | Crosslinked copolymers of α,β-olefinically unsaturated dicarboxylic anhydrides |
| US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| WO1983000150A1 (en) * | 1981-07-02 | 1983-01-20 | Walton, Alan, G. | Glycosaminoglycan drug complexes |
| ATE37983T1 (de) * | 1982-04-22 | 1988-11-15 | Ici Plc | Mittel mit verzoegerter freigabe. |
| US4569794A (en) * | 1984-12-05 | 1986-02-11 | Eli Lilly And Company | Process for purifying proteins and compounds useful in such process |
| US5037741A (en) * | 1986-08-18 | 1991-08-06 | The Coca Cola Company | Enzymatic method for the synthesis and separation of peptides |
| JP2544929B2 (ja) * | 1987-06-17 | 1996-10-16 | 第一化学薬品 株式会社 | 新規生理活性ペプチド |
| US5114923A (en) | 1988-05-31 | 1992-05-19 | California Biotechnology Inc. | Recombinant techniques for production of novel natriuretic and vasodilator peptides |
| CA1339210C (en) | 1988-05-31 | 1997-08-05 | John Lewicki | Recombinant techniques for production of novel natriuretic and vasodilator peptides |
| JP2539665B2 (ja) * | 1988-06-20 | 1996-10-02 | 日本臓器製薬株式会社 | 神経疾患治療剤 |
| JP2561513B2 (ja) | 1988-07-04 | 1996-12-11 | 塩野義製薬株式会社 | γ−ＡＮＰを認識するモノクローナル抗体 |
| JPH0720857B2 (ja) | 1988-08-11 | 1995-03-08 | テルモ株式会社 | リポソームおよびその製法 |
| IT1229514B (it) | 1989-01-30 | 1991-09-03 | Farmhispania S A A Montme | Glicoconiugati anfifilici sintetici per impiego neurologico. |
| US20020086843A1 (en) | 1989-03-01 | 2002-07-04 | Daiichi Pure Chemicals Co., Ltd. | Physiologically active polypeptide and DNA |
| ES2076981T5 (es) | 1989-03-01 | 2000-02-01 | Shionogi & Co | Polipeptido fisiologicamente activo y su adn. |
| US5342940A (en) * | 1989-05-27 | 1994-08-30 | Sumitomo Pharmaceuticals Company, Limited | Polyethylene glycol derivatives, process for preparing the same |
| DE69032598T2 (de) | 1989-06-23 | 1999-03-11 | Genentech Inc | Zusammensetzungen und methoden zur synthese des b-rezeptors für das natriuretische protein und verwendungsmethoden |
| US5108568A (en) * | 1989-07-07 | 1992-04-28 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Controlled method of reducing electrophoretic mobility of macromolecules, particles or cells |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| SE8904407L (sv) | 1989-12-29 | 1991-06-30 | Qingpingfeng | Medikament foer behandling av hjaertsvikt |
| IE912365A1 (en) * | 1990-07-23 | 1992-01-29 | Zeneca Ltd | Continuous release pharmaceutical compositions |
| US5202239A (en) | 1990-08-07 | 1993-04-13 | Scios Nova Inc. | Expression of recombinant polypeptides with improved purification |
| JP3026354B2 (ja) | 1990-09-27 | 2000-03-27 | 壽之 松尾 | ヒトｃｎｐ遺伝子及び前駆体蛋白 |
| US5853746A (en) | 1991-01-31 | 1998-12-29 | Robert Francis Shaw | Methods and compositions for the treatment and repair of defects or lesions in cartilage or bone using functional barrier |
| ATE253639T1 (de) | 1991-08-19 | 2003-11-15 | Daiichi Suntory Pharma Co Ltd | Verfahren zur herstellung von peptiden |
| JP2665850B2 (ja) | 1991-11-14 | 1997-10-22 | 塩野義製薬株式会社 | ｈＢＮＰのＣ端を認識するモノクロ−ナル抗体 |
| GB9211686D0 (en) | 1992-06-03 | 1992-07-15 | Medisinsk Innovation A S | Chemical compounds |
| CA2188143A1 (en) | 1992-12-09 | 1995-11-02 | Wolf-Georg Forssmann | Use of brain natriuretic peptides (bnp), phosphorylated urodilatine, phosphorylated cdd/anp and combinations thereof |
| US5681811A (en) | 1993-05-10 | 1997-10-28 | Protein Delivery, Inc. | Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same |
| US6191105B1 (en) * | 1993-05-10 | 2001-02-20 | Protein Delivery, Inc. | Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin |
| US5359030A (en) * | 1993-05-10 | 1994-10-25 | Protein Delivery, Inc. | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
| US5512459A (en) * | 1993-07-20 | 1996-04-30 | Bionebraska, Inc. | Enzymatic method for modification or recombinant polypeptides |
| EP0725638B1 (de) | 1993-08-28 | 2001-03-28 | The University Of Sheffield | Behandlung von laminitis |
| US6525022B1 (en) | 1993-11-12 | 2003-02-25 | Genentech, Inc. | Receptor specific atrial natriuretic peptides |
| US6037145A (en) | 1994-09-07 | 2000-03-14 | Suntory Limited | Process for production of protein |
| DE69509626T2 (de) * | 1994-12-09 | 2000-01-13 | Shionogi & Co | Sandwich-Immunotestverfahren für N-Peptide |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| WO1997014740A1 (en) | 1995-10-19 | 1997-04-24 | Receptagen Corporation | Discrete-length polyethylene glycols |
| CA2248140C (en) * | 1996-03-04 | 2005-02-01 | Ronald P. Mischak | Assay and reagents for quantifying hbnp |
| WO1997034618A1 (en) | 1996-03-22 | 1997-09-25 | The General Hospital Corporation | Administration of polypeptide growth factors following central nervous system ischemia or trauma |
| US6028055A (en) | 1996-10-22 | 2000-02-22 | Genetech, Inc. | Receptor selective BNP |
| EP0939770A1 (de) | 1996-10-22 | 1999-09-08 | Genentech, Inc. | Rezeptor spezifische bnp |
| AU6820898A (en) | 1997-04-04 | 1998-10-30 | Novo Nordisk A/S | Natriuretic peptide derivatives |
| US20040005669A1 (en) * | 1997-08-07 | 2004-01-08 | Stefan Stahl | Recombinant expression of insulin C-peptide |
| GB9716790D0 (en) | 1997-08-07 | 1997-10-15 | Creative Peptides Sweden Ab | Recombinant DNA molecules comprising multimeric copies of a gene sequence and expression thereof |
| US6013630A (en) | 1997-08-21 | 2000-01-11 | Curagen Corporation | Atrial natriuretic factor mutants and ischemic stroke |
| AU751660B2 (en) | 1997-10-24 | 2002-08-22 | Shionogi & Co., Ltd. | Method for inhibiting decomposition of natriuretic peptides and improved method for assaying natriuretic peptides with the use of the same |
| US6495514B1 (en) * | 1998-01-21 | 2002-12-17 | Mercer University | Method for reducing inflammation and inducing an analgesic effect and compounds thereof |
| JP4394279B2 (ja) * | 1998-03-09 | 2010-01-06 | ジーランド ファーマ アクティーゼルスカブ | 酵素加水分解に対する傾向が減少した薬理学的に活性なペプチド複合体 |
| US6117644A (en) * | 1998-06-04 | 2000-09-12 | Ottawa Heart Institute Research Corporation | Predicting and detecting cardiac allograft rejection |
| US6703381B1 (en) * | 1998-08-14 | 2004-03-09 | Nobex Corporation | Methods for delivery therapeutic compounds across the blood-brain barrier |
| SE9802946D0 (sv) | 1998-09-02 | 1998-09-02 | Europrofil Ab | Förfarande och listarrangemang för att täcka skarvar eller skapa övergångar i samband med ytbeläggningar |
| JP3799465B2 (ja) * | 1998-09-28 | 2006-07-19 | 参天製薬株式会社 | ナトリウム利尿ペプチドを有効成分とする涙液分泌促進または角結膜障害治療用点眼剤 |
| AU2624400A (en) | 1999-01-26 | 2000-08-07 | Eli Lilly And Company | Monodisperse hexameric acylated insulin analog formulations |
| EP1591453A1 (de) * | 1999-05-17 | 2005-11-02 | ConjuChem Inc. | Modifizierte YY-Peptide und ihre Konjugate |
| WO2004011498A2 (en) | 2002-07-31 | 2004-02-05 | Conjuchem Inc. | Long lasting natriuretic peptide derivatives |
| AU5043900A (en) | 1999-05-24 | 2000-12-12 | Mayo Foundation For Medical Education And Research | Adenovirus vectors encoding brain natriuretic peptide |
| US6309633B1 (en) * | 1999-06-19 | 2001-10-30 | Nobex Corporation | Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same |
| KR100345214B1 (ko) * | 1999-08-17 | 2002-07-25 | 이강춘 | 생체적합성 고분자가 수식된 펩타이드의 비점막 전달 |
| US6610043B1 (en) * | 1999-08-23 | 2003-08-26 | Bistech, Inc. | Tissue volume reduction |
| US6713454B1 (en) * | 1999-09-13 | 2004-03-30 | Nobex Corporation | Prodrugs of etoposide and etoposide analogs |
| US6541508B2 (en) * | 1999-09-13 | 2003-04-01 | Nobex Corporation | Taxane prodrugs |
| US7127290B2 (en) | 1999-10-01 | 2006-10-24 | Cardiac Pacemakers, Inc. | Cardiac rhythm management systems and methods predicting congestive heart failure status |
| US6638906B1 (en) * | 1999-12-13 | 2003-10-28 | Nobex Corporation | Amphiphilic polymers and polypeptide conjugates comprising same |
| US6407211B1 (en) | 1999-12-17 | 2002-06-18 | Mayo Foundation For Medical Education And Research | Chimeric natriuretic peptides |
| JP4237375B2 (ja) * | 2000-03-31 | 2009-03-11 | アスビオファーマ株式会社 | 虚血性疾患の処置又は予防に用いる医薬組成物 |
| ES2333337T3 (es) * | 2000-08-29 | 2010-02-19 | Biocon Limited | Uso de una composicion farmaceutica que contiene un derivado de acido para-aminofenilacetico para tratar afecciones inflamatorias del tracto gastrointestinal. |
| US6867183B2 (en) * | 2001-02-15 | 2005-03-15 | Nobex Corporation | Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith |
| US7060675B2 (en) * | 2001-02-15 | 2006-06-13 | Nobex Corporation | Methods of treating diabetes mellitus |
| US20030219734A1 (en) * | 2001-04-13 | 2003-11-27 | Biosite Incorporated | Polypeptides related to natriuretic peptides and methods of their identification and use |
| US7632647B2 (en) * | 2001-04-13 | 2009-12-15 | Biosite Incorporated | Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes |
| FR2823993B1 (fr) * | 2001-04-27 | 2003-06-20 | Rhodia Chimie Sa | Dispersion colloidale aqueuse stable, son procede de preparation |
| EP1666881B1 (de) * | 2001-05-04 | 2010-02-17 | Biosite Incorporated | Diagnostische Marker der akuten koronaren Syndrome und ihre Verwendungen |
| US6828305B2 (en) * | 2001-06-04 | 2004-12-07 | Nobex Corporation | Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
| US6713452B2 (en) * | 2001-06-04 | 2004-03-30 | Nobex Corporation | Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
| US6828297B2 (en) * | 2001-06-04 | 2004-12-07 | Nobex Corporation | Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
| US6835802B2 (en) * | 2001-06-04 | 2004-12-28 | Nobex Corporation | Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties |
| US7713932B2 (en) * | 2001-06-04 | 2010-05-11 | Biocon Limited | Calcitonin drug-oligomer conjugates, and uses thereof |
| US6858580B2 (en) * | 2001-06-04 | 2005-02-22 | Nobex Corporation | Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
| US6737913B2 (en) * | 2001-06-15 | 2004-05-18 | Silicon Laboratories, Inc. | Differential mode circuitry and method of calibrating same without matched external current sources |
| US7030082B2 (en) * | 2001-09-07 | 2006-04-18 | Nobex Corporation | Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith |
| US7196059B2 (en) * | 2001-09-07 | 2007-03-27 | Biocon Limited | Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith |
| US6770625B2 (en) * | 2001-09-07 | 2004-08-03 | Nobex Corporation | Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith |
| US6913903B2 (en) * | 2001-09-07 | 2005-07-05 | Nobex Corporation | Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same |
| US7312192B2 (en) * | 2001-09-07 | 2007-12-25 | Biocon Limited | Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same |
| DE60234198D1 (de) | 2001-09-07 | 2009-12-10 | Biocon Ltd | Verfahren zur synthese von insulinpolypeptid-oligomer-konjugaten und proinsulinpolypeptid-oligomer-konjugaten und verfahren zu deren synthese |
| US20040063630A1 (en) * | 2002-03-18 | 2004-04-01 | Scios, Inc. | Treatment of congestive heart failure with natriuretic peptide and a diuretic |
| US20040152769A1 (en) | 2002-11-09 | 2004-08-05 | Ekwuribe Nnochiri Nkem | Modified carbamate-containing prodrugs and methods of synthesizing same |
| AU2003297583B2 (en) | 2002-11-26 | 2010-01-14 | Biocon, Ltd | Modified naturetic compounds, conjugates, and uses thereof |
| US20060198819A1 (en) * | 2003-08-08 | 2006-09-07 | Novo Nordisk Healthcare A/G | Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest |
-
2003
- 2003-11-12 AU AU2003297583A patent/AU2003297583B2/en not_active Ceased
- 2003-11-12 EP EP03812053A patent/EP1569683B1/de not_active Expired - Lifetime
- 2003-11-12 SG SG200703827-6A patent/SG159387A1/en unknown
- 2003-11-12 CA CA002504287A patent/CA2504287A1/en not_active Abandoned
- 2003-11-12 BR BR0316560-4A patent/BR0316560A/pt not_active IP Right Cessation
- 2003-11-12 PL PL377813A patent/PL377813A1/pl not_active Application Discontinuation
- 2003-11-12 WO PCT/US2003/037996 patent/WO2004047871A2/en active Application Filing
- 2003-11-12 CN CNB2003801091794A patent/CN100558398C/zh not_active Expired - Fee Related
- 2003-11-12 DE DE60331584T patent/DE60331584D1/de not_active Expired - Lifetime
- 2003-11-12 AT AT03812053T patent/ATE459370T1/de not_active IP Right Cessation
- 2003-11-26 JP JP2004555809A patent/JP2006515579A/ja active Pending
- 2003-11-26 US US10/723,933 patent/US7662773B2/en not_active Expired - Fee Related
-
2006
- 2006-07-04 HK HK06107556.5A patent/HK1087327A1/xx not_active IP Right Cessation
-
2010
- 2010-04-13 AU AU2010201455A patent/AU2010201455A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2006515579A (ja) | 2006-06-01 |
| AU2003297583A1 (en) | 2004-06-18 |
| CA2504287A1 (en) | 2004-06-10 |
| PL377813A1 (pl) | 2006-02-20 |
| US20040203081A1 (en) | 2004-10-14 |
| ATE459370T1 (de) | 2010-03-15 |
| WO2004047871A3 (en) | 2005-03-17 |
| EP1569683A2 (de) | 2005-09-07 |
| SG159387A1 (en) | 2010-03-30 |
| AU2010201455A1 (en) | 2010-05-06 |
| CN1741814A (zh) | 2006-03-01 |
| WO2004047871A2 (en) | 2004-06-10 |
| CN100558398C (zh) | 2009-11-11 |
| HK1087327A1 (en) | 2006-10-13 |
| AU2003297583B2 (en) | 2010-01-14 |
| EP1569683B1 (de) | 2010-03-03 |
| US7662773B2 (en) | 2010-02-16 |
| BR0316560A (pt) | 2005-10-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60331584D1 (de) | Modifizierte natriuretic verbindungen, konjugate und ihre verwendungen | |
| WO2005116655A3 (en) | Natriuretic compounds, conjugates, and uses thereof | |
| WO2006076471A3 (en) | Bnp conjugates and methods of use | |
| WO2005058958A3 (en) | Novel glp-1 analogues linked to albumin-like agents | |
| KR20090098843A (ko) | 신규 화합물 및 식습관에 대한 이의 효과 | |
| JP2016183192A (ja) | 新規のグルカゴンアナログ | |
| RU2009105696A (ru) | N-концевое полисиалилирование | |
| TWI747929B (zh) | 一種人胰島素或其類似物的醯化衍生物 | |
| RU2014129893A (ru) | Фармацевтическая композиция и способ лечения связанных с гормоном роста заболеваний у человека | |
| JP2008500375A5 (de) | ||
| ATE541582T1 (de) | Stabilisierte pharmazeutische glp-1 peptid zusammensetzungen | |
| RU2015142992A (ru) | Сайт-специфическая конъюгация антитело-лекарственное средство посредством гликоинженерии | |
| NZ599345A (en) | Immunogens from uropathogenic Escherichia Coli | |
| MX2009002999A (es) | Analogos de insulina resistentes a proteasa. | |
| WO2009158704A3 (en) | Therapeutic agents comprising elastin-like peptides | |
| EA200400565A1 (ru) | Конъюгаты химически модифицированного гормона роста человека | |
| RU2012109553A (ru) | Модифицированные вазоактивные интестинальные пептиды | |
| JP2016512426A5 (de) | ||
| NO20021335D0 (no) | C-peptid for forbedret fremstilling av insulin og insulinanaloger | |
| WO2003076585A3 (en) | Controlled modulation of amino acid side chain length of peptide antigens | |
| JP2015514690A (ja) | 生理活性ポリペプチド複合体の製造のための改善工程 | |
| BRPI0506694A (pt) | análogos de peptìdeo-1 semelhante ao glucagon com longa duração de ação | |
| WO2007005056A3 (en) | Platinum complexes with mononitrile-containing ligands | |
| TW200502251A (en) | Natriuretic compound conjugates, conjugates, and uses thereof | |
| WO2000006185A3 (en) | Methods of using lanreotide, a somatostatin analogue |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |